Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Chen

Showing results (171-180 of 274) with videos related to

Pageof 28
Sort By:
Molecular Neurodegeneration|August 6, 2024
Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer's diseaseAnantharaman Shantaraman, Eric B Dammer, Obiadada Ugochukwu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2011
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomasShivaani Kummar, Martin E Gutierrez, Alice Chen, et al.
Nature Communications|January 10, 2019
Publisher Correction: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapyHao Geng, Changhui Xue, Janet Mendonca, et al.
JAMA Neurology|May 24, 2013
Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutationsLama M Chahine, Judy Qiang, Emily Ashbridge, et al.
Cancer|October 11, 2018
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanomaAhmad A Tarhini, Paul Frankel, Christopher Ruel, et al.
Nature Communications|November 28, 2018
Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapyHao Geng, Changhui Xue, Janet Mendonca, et al.
Medrxiv : the Preprint Server for Health Sciences|September 15, 2025
Temporal Modeling of Amyloid and Tau Trajectories in Alzheimer's Disease using PET and Plasma BiomarkersChristopher A Brown, Katheryn A Q Cousins, Magdalena Korecka, et al.
JCO Global Oncology|April 23, 2026
Mapping National Definitions, Classifications, and Policy Approaches to Poor-Prognosis Cancers Across the G7 Cancer Initiative CountriesMarisa Nishio, Hiromi Sugiyama, Valerie McCormack, et al.
Molecular Interventions|January 18, 2008
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practiceRobert Kinders, Ralph E Parchment, Jay Ji, et al.
Acta Neuropathologica|March 17, 2010
Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairmentWilliam T Hu, Alice Chen-Plotkin, Steven E Arnold, et al.
Pageof 28

Showing results (171-180 of 274) with videos related to

Sort By:
Pageof 28
Molecular Neurodegeneration|August 6, 2024
Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer's diseaseAnantharaman Shantaraman, Eric B Dammer, Obiadada Ugochukwu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2011
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomasShivaani Kummar, Martin E Gutierrez, Alice Chen, et al.
Nature Communications|January 10, 2019
Publisher Correction: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapyHao Geng, Changhui Xue, Janet Mendonca, et al.
JAMA Neurology|May 24, 2013
Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutationsLama M Chahine, Judy Qiang, Emily Ashbridge, et al.
Cancer|October 11, 2018
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanomaAhmad A Tarhini, Paul Frankel, Christopher Ruel, et al.
Nature Communications|November 28, 2018
Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapyHao Geng, Changhui Xue, Janet Mendonca, et al.
Medrxiv : the Preprint Server for Health Sciences|September 15, 2025
Temporal Modeling of Amyloid and Tau Trajectories in Alzheimer's Disease using PET and Plasma BiomarkersChristopher A Brown, Katheryn A Q Cousins, Magdalena Korecka, et al.
JCO Global Oncology|April 23, 2026
Mapping National Definitions, Classifications, and Policy Approaches to Poor-Prognosis Cancers Across the G7 Cancer Initiative CountriesMarisa Nishio, Hiromi Sugiyama, Valerie McCormack, et al.
Molecular Interventions|January 18, 2008
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practiceRobert Kinders, Ralph E Parchment, Jay Ji, et al.
Acta Neuropathologica|March 17, 2010
Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairmentWilliam T Hu, Alice Chen-Plotkin, Steven E Arnold, et al.
Pageof 28